Advertisement
Advertisement
SNOA
Sonoma Pharmaceuticals, Inc. Common Stock
2.29
USDSponsored
-0.05
-2.18%
Mar 25, 15:59 UTC -4
Closed
After-Market
2.30
+0.01
+0.66%
SNOA Earnings Reports
Positive Surprise Ratio
SNOA beat 11 of 21 last estimates.
52%
Next Report
Date of Next Report
Jun 15, 2026
Estimate for Q4 26 (Revenue/ EPS)
$4.68M
/-$0.20
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Sonoma Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Feb 03, 2026, SNOA reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.31 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 4.41 million, with a --% difference. The market reacted with a -0.93% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 3 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 4.68 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were Sonoma Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Sonoma Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Sonoma Pharmaceuticals, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -0.93%, changed from $3.23 before the earnings release to $3.20 the day after.
When is Sonoma Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jun 15, 2026.
What are the forecasts for Sonoma Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 3
analysts, Sonoma Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $4.68M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement